Screener
Supernus Pharmaceuticals SUPN Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total other income (expense), net | 2,382 | 4,425 |
| Loss before income taxes | (5,950) | (5,831) |
| Income tax expense (benefit) | (3,657) | 5,996 |
| Net loss | $(2,293) | $(11,827) |
| Loss per share | ||
| Basic | $(0.04) | $(0.21) |
| Diluted | $(0.04) | $(0.21) |
| Weighted average shares outstanding |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's business segments — net loss?
- Supernus Pharmaceuticals (SUPN) reported business segments — net loss of -$2.29M in Q1 2026.
- How has Supernus Pharmaceuticals's business segments — net loss changed year-over-year?
- Supernus Pharmaceuticals's business segments — net loss increased by 80.6% year-over-year, from -$11.83M to -$2.29M.
- What is the long-term trend for Supernus Pharmaceuticals's business segments — net loss?
- Over 3 years (2022 to 2025), Supernus Pharmaceuticals's business segments — net loss has grown at a -14.0% compound annual growth rate (CAGR), from $60.71M to -$38.55M.
- What does business segments — net loss mean?
- Indicates the bottom-line financial result for the segment after accounting for all revenues and operating expenses. A net loss signifies that the costs of commercialization and development currently exceed the revenue generated by the segment.
Ask your AI about Supernus Pharmaceuticals's business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude